Resource hub

Linkedin Facebook X-twitter Instagram Strategies for Efficient Viral Vector Production for Gene Therapies Viral vectors are essential tools in gene therapy, offering promising treatment options for various genetic diseases (Bulcha et al., 2021). However, scaling up production to meet growing demand introduces several challenges. Complexities in production, low yields, and stringent regulatory requirements make viral […]

Linkedin Facebook X-twitter Instagram Modern Medicine Transformed: How Viral Vectors Drive Gene Therapy Gene therapy is transforming modern medicine, with viral vectors playing a central role in this advancement. These engineered viruses deliver therapeutic genetic sequences to specific cells, offering potential treatments for genetic disorders, cancers, and neurodegenerative diseases. This article will explore how viral

Linkedin Facebook X-twitter Instagram Viral Vector Production for Biomedicine: Key Applications and Industry Trends Viral vector production is revolutionizing biomedical science by enabling precise gene delivery methods, which hold promise in treating genetic diseases and developing vaccines (Bulcha et al., 2021). While the concept behind these therapies is relatively simple, they pose significant technological and

Linkedin Facebook X-twitter Instagram Stem cell technologies are responsible for some of the most exciting areas of modern healthcare. A core element of this is the use of allogeneic stem cell therapy in regenerative medicine. These therapies use donor-derived somatic cells, which are dedifferentiated into induced pluripotent stem cells (iPSC). From here, iPSCs can be

Linkedin Facebook X-twitter Instagram Induced pluripotent stem cell (iPSC)-based allogeneic cell therapies are set to transform many fields of healthcare, especially regenerative medicine1. These therapies mean that donor-derived iPSCs can be modified and scaled up for use as “off-the-shelf” treatments for neurodegenerative, cardiovascular, and retinal diseases, to name just a few. Automation is also emerging

Linkedin Facebook X-twitter Instagram Induced pluripotent stem cells (iPSCs) are an incredibly powerful technology that continues to transform many facets of biomedicine. One particularly exciting area is the use of iPSC-derived cells as therapeutic agents. The development of allogeneic iPS cell-based therapies offers “off-the-shelf” therapies for regenerative medicine to treat conditions like cardiovascular disease, retinal degradation, and neurodegenerative

Linkedin Facebook X-twitter Instagram Induced pluripotent stem cells (iPSCs) are revolutionizing biomedical research and healthcare by enabling the generation and modification of virtually any cell type to suit various applications. iPSCs are used for disease modeling, drug discovery, and personalized medicine, and the therapeutic potential of iPSCs is vast. Allogeneic cell therapies using iPSCs allow

Linkedin Facebook X-twitter Instagram Streamlining Monoclonal Antibody Production: From Quality Control to Cost Management Monoclonal antibody production is a critical process in modern medicine, supporting the development of therapeutics that have proven invaluable across oncology, immunology, and virology (Mekala et al., 2024). Ensuring high-quality and cost-effective production involves rigorous quality control, optimizing production workflows, and

Linkedin Facebook X-twitter Instagram Optimizing Your Monoclonal Antibody Production Workflow Monoclonal antibody production is a multi-step process that involves developing cell lines, optimizing culture conditions, and ensuring stringent quality control to produce consistent batches of high-quality, high-yield monoclonal antibodies. The production of monoclonal antibodies is crucial due to their therapeutic applications across cancer, immunology, and

Linkedin Facebook X-twitter Instagram Therapeutic Monoclonal Antibody Applications Monoclonal antibodies are highly specific antibodies designed to bind to a particular epitope on an antigen with high affinity (Castelli et al., 2019). Monoclonal antibodies are produced using hybridoma technology or Chinese Hamster Ovary (CHO) cells. Hybridoma technology was introduced by Köhler and Milstein in 1975 and

Linkedin Facebook X-twitter Instagram Hybridoma Technology: Quality Control and Best Practices Hybridoma technology was first described in 1975 by Georges Köhler and Cesar Milstein, who were jointly awarded the Nobel Prize in Physiology or Medicine in 1984 for their discovery (Köhler & Milstein, 1975; The Nobel Prize in Physiology or Medicine 1984, n.d.). It enables

Linkedin Facebook X-twitter Instagram Cell Line Development: Comprehensive Insights and Advances Cell line development is a cornerstone of several modern biomedical applications. It provides essential models for studying diseases and tools for developing the latest therapeutic products1. Researchers leverage the unique benefits of mammalian cell lines and innovations in gene editing, such as clustered regularly